10-QPeriod: Q1 FY2026

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2026

Filed April 30, 2026For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) has filed its 10-Q for the period ending March 31, 2026. Investors should pay close attention to the financial performance and strategic initiatives outlined in this report. The filing provides a detailed look at the company's earnings, financial position, and cash flows, along with management's commentary on the results and outlook. Key areas to monitor include revenue generation from existing and pipeline products, ongoing research and development investments, and any significant legal or risk factors that could impact future operations. While the full financial statements are included, the Management's Discussion and Analysis (MD&A) section is crucial for understanding the drivers behind the reported numbers. Investors should look for updates on drug development milestones, regulatory approvals, and commercial performance of key therapeutic areas. The company's ability to navigate market risks and leverage its competitive advantages will be central to its continued growth and shareholder value creation.

Financial Highlights

54 data points
Beta

Revenue

$11.49B

70.2% Gross Margin

Net Income

$2.68B

23.3% Net Margin

EPS (Diluted)

$1.31

Total Assets

$86.48B

Cash & Equivalents

$9.57B

Free Cash Flow

$757.00M

Financial Statements
Beta
Revenue$11.49B
Cost of Revenue$3.42B
Gross Profit$8.07B
R&D Expenses$2.65B
SG&A Expenses$1.62B
Operating Expenses$8.25B
Net Income$2.68B
EPS (Basic)$1.31
EPS (Diluted)$1.31
Shares Outstanding (Basic)2.04B
Shares Outstanding (Diluted)2.05B

Key Highlights

  • 1The report covers the financial performance for the quarter ending March 31, 2026.
  • 2Key financial statements, including Consolidated Statements of Earnings, Balance Sheets, and Cash Flows, are presented.
  • 3Management's Discussion and Analysis (MD&A) provides insights into the company's financial condition and operational results.
  • 4Disclosure on market risk and controls and procedures are detailed in the filing.
  • 5Information on legal proceedings and risk factors are outlined, which could impact the company's future performance.
  • 6Details regarding unregistered sales of equity securities and the use of proceeds are included.
  • 7The filing is comprehensive, covering both financial and other material information relevant to investors.

Frequently Asked Questions

This 10-Q includes the Consolidated Statements of Earnings and Comprehensive Income/(Loss), Consolidated Balance Sheets, and Consolidated Statements of Cash Flows for the period ending March 31, 2026. These statements provide investors with the company's profitability, assets and liabilities, and cash generation and usage.

Management's Discussion and Analysis of Financial Condition and Results of Operations, typically found in Item 2 of Part I, offers management's narrative on the company's financial results, liquidity, capital resources, and known trends and uncertainties.

Item 1A, Risk Factors, details the various risks and uncertainties that could materially affect Bristol Myers Squibb's business, financial condition, or results of operations. Investors should carefully review this section to understand potential challenges.

Item 1, Legal Proceedings, in Part II of the filing will provide information on any significant legal actions or proceedings that the company is involved in, which could have financial implications.